Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 20, 2026
Why Is Tempus AI (TEM) Stock Down -8.94% Today?

Why Is Tempus AI (TEM) Stock Down -8.94% Today?

Key Takeaways

  • TEM shares plunged 8.94% to approximately $47.78 in Monday's session, extending a multi-day selloff from the prior week.
  • The primary catalyst is the announcement that Tempus AI will acquire Personalis (PSNL) in an all-stock deal valued at roughly $1.5 billion in enterprise value, triggering dilution concerns and a negative market reception.
  • The deal price of $16.25 per share for Personalis represents only a 6% premium to Friday's close, and both stocks sold off sharply — an unusual dual-decline that reflects investor skepticism about the deal's strategic and financial merits.
  • Broader pressures include a deteriorating technical backdrop, with TEM already down more than 10% over the prior week and sitting roughly 44% below its 52-week high of $104.32.
  • Traders are now watching the company's upcoming Q2 2026 earnings report, expected around July 30, for updates on revenue trajectory, margin progress, and integration plans for the Personalis acquisition.

Opening Summary

TEM, Tempus AI, Inc. — a healthcare technology company that applies artificial intelligence to precision medicine, including genomic sequencing, clinical data analytics, and AI-driven diagnostics — saw its shares tumble approximately 8.94% in trading on Monday. The stock fell to roughly $47.78, down from the prior session's close of $52.47 on Friday, July 17, 2026. The sharp decline was triggered by the company's announcement that it would acquire cancer-genomics firm PSNL in a deal valued at around $1.5 billion, structured entirely in stock. The negative market reaction reflects dilution fears, concerns about deal economics, and a broader lack of confidence in high-multiple, unprofitable growth names in the current market environment.

Acquisition of Personalis Triggers Sell-Off

Before Monday's opening bell, Tempus AI disclosed a definitive agreement to acquire all outstanding shares of Personalis not already owned by Tempus at $16.25 per share — a transaction that places a $1.5 billion enterprise value on Personalis, net of Tempus's existing ownership position. The deal is structured as an all-stock transaction, with Tempus retaining the option to pay up to 50% in cash at its discretion. Shareholders of Personalis will receive a floating exchange ratio of Tempus AI common stock for each share they hold, capped at a maximum ratio of 0.3356.

While the acquisition strategically extends Tempus's reach into the minimal residual disease (MRD) testing market — an estimated $20 billion opportunity — and builds on a partnership the two companies established in November 2023, investors reacted negatively. All-stock acquisitions of this size raise immediate concerns about shareholder dilution, especially for a company that is not yet profitable. The offer price also represented a modest 6% premium to PSNL's Friday close, which some market participants viewed as insufficient given the strategic value of Personalis's NeXT Personal MRD testing platform. In an unusual twist, both the acquirer and the target sold off — Personalis shares fell roughly 12%, far exceeding the gap between its prior close and the offer price, signaling investor disappointment with the terms.

Broader Downtrend and Negative Sentiment

Monday's sell-off did not occur in isolation. TEM entered the session already under heavy pressure, having declined 2.09% on Friday, 6.39% on Wednesday, and 2.42% on Tuesday of the prior week. The stock is down roughly 11% year to date and sits approximately 44% below its 52-week high of $104.32, reached in October 2025. The broad deterioration in sentiment traces back to the company's Q4 2025 earnings report in March 2026, when Tempus missed adjusted EPS estimates and issued full-year adjusted EBITDA guidance of roughly $5 million — below the approximately $6 million consensus. The company's price-to-sales ratio of approximately 6.3x remains well above the life sciences peer average near 3.6x, leaving little margin for error when guidance or strategic moves underwhelm.

Market Context and Trading Activity

Volume in TEM was elevated compared to recent sessions, reflecting conviction-driven selling rather than passive drift. The stock's beta of 3.46 amplifies both upward and downward moves relative to the broader market, and Monday's decline decisively breached the psychologically important $50 level — a threshold that had provided support during prior pullbacks. With the stock now trading near the lower end of its 52-week range ($41.73–$104.32), technical analysts are closely monitoring whether the $45–$47 zone can serve as a floor. Broader healthcare and AI-linked names traded mixed on Monday, suggesting the move in TEM was primarily deal-driven and company-specific rather than a sector-wide rotation.

Trending AI Robots

In volatile market environments like the one affecting TEM today, many traders turn to AI-driven tools for actionable signals and disciplined strategy execution. Tickeron's Trending AI Robots page curates a selection of the platform's strongest-performing AI trading bots, drawn from a larger universe of hundreds of automated strategies covering thousands of tickers. Each bot operates with distinct parameters — varying by strategy type, timeframe, performance metrics, and traded symbols — and only those demonstrating robust real-time results under current market conditions are featured in this curated section. Whether you are navigating post-acquisition volatility or scanning for new opportunities, the Trending AI Robots page provides a window into how AI-powered trading tools are performing right now.

What Comes Next for TEM

The immediate focus for TEM shifts to the company's upcoming Q2 2026 earnings report, expected around July 30. Investors will want to see whether revenue growth has stabilized after a sequential decline from Q4 2025 ($367.21 million) to Q1 2026 ($348.12 million), and whether management can articulate a clearer path to profitability. The integration timeline for Personalis — with closing expected in late 2026 or early 2027 — means the deal will remain a source of uncertainty for several quarters, particularly regarding any impact on Tempus's balance sheet if the company elects to fund part of the consideration with debt. Analyst price targets have been trending lower in recent months, with the blended consensus near $67.06, but conviction levels vary widely. Risks include slower-than-expected MRD market adoption, continued margin compression, and the possibility that the Personalis acquisition integration proves more complex or costly than anticipated.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TEM

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


TEM in upward trend: price rose above 50-day moving average on August 07, 2026

TEM moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend. In of 18 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TEM's RSI Oscillator exited the oversold zone, of 12 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on TEM as a result. In of 33 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for TEM just turned positive on August 06, 2026. Looking at past instances where TEM's MACD turned positive, the stock continued to rise in of 21 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in of 120 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 10-day moving average for TEM crossed bearishly below the 50-day moving average on July 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TEM broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TEM entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.124) is normal, around the industry mean (8.096). P/E Ratio (39.298) is within average values for comparable stocks, (48.116). TEM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.623). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (6.789) is also within normal values, averaging (6.513).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 2.65B. The market cap for tickers in the group ranges from 708 to 39.23B. VEEV holds the highest valuation in this group at 39.23B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was 4%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 23%. CTEV experienced the highest price growth at 32%, while VSEE experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 11%. For the same stocks of the Industry, the average monthly volume growth was 71% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 77
Price Growth Rating: 54
SMR Rating: 88
Profit Risk Rating: 98
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
TEM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Profile
Details
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.